FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2463147654> ?p ?o ?g. }

• W2463147654 endingPage "8" @default.
• W2463147654 startingPage "291" @default.
• W2463147654 abstract "Epidemiological and experimental data indicate that high body fat or high dietary fat can be ascribed to the induction of human cancers. Increased level of products of lipid peroxidation and cholesterol-enriched lipid domains in the plasma membrane can favorthe malignant transformation of cells. An effective chemopreventive agent with hypolipaedemic effect will be worthwhile to intervene early in the process of carcinogenesis to eliminate the pre-malignant cells. Apoptotic promoting and antitumor activities of a HMG-Co A reductase inhibitor, atorvatstain were investigated. The antitumor activity was evaluated using Daltons' Lymphoma Ascites (DLA) cell line transplanted ascites tumor model in mice. Proapoptotic activity was evaluated in DLA cell line induced ascites animals after the treatment of atorvastatin (4 and 16 mg/kg, i.p). Apoptosis was analyzed morphologically by staining with giemsa and biochemically by observing the laddering of DNA in agarose gel electrophoresis. In vitro short term cytotoxic activity of atorvatstain was studied by trypan blue dye exclusion method. Doxorubicin was used as the reference standard. Atorvastatin significantly (P < 0.01) inhibited the ascites tumor growth at 16 mg/kg body wt (i.p). The percent increase in life span (%ILS) in the 16 mg/kg treated group was 41.1%. Single dose of atorvastatin (16 mg/kg body wt) was also effective to promote the apoptosis of DLA cells in the ascites tumor bearing mice that was evident from the multiple fragmentation of DNA in agarose gel electrophoresis. Further the morphological analysis of DLA cells aspirated from the atorvastatin treated ascites tumor bearing animals showed 36.34 +/- 6.78% apoptotic cells compared to the control animals (10.50 +/- 3.53%). Concentration of atorvastatin required for the 50% of the cytotoxicity was 30 +/- 2 microg/ml. Results of the study concluded that the antitumor activity of atorvastatin may be due to its proapoptotic and cytotoxic activities. These pleiotropic activities of the hypolipedaemic drug atorvastatin suggest its possible use as a cancer chemopreventive agent." @default.
• W2463147654 created "2016-07-22" @default.
• W2463147654 creator A5003656202 @default.
• W2463147654 creator A5085203627 @default.
• W2463147654 date "2008-01-01" @default.
• W2463147654 modified "2023-09-26" @default.
• W2463147654 title "Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice." @default.
• W2463147654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19227009" @default.
• W2463147654 hasPublicationYear "2008" @default.
• W2463147654 type Work @default.
• W2463147654 sameAs 2463147654 @default.
• W2463147654 citedByCount "2" @default.
• W2463147654 countsByYear W24631476542012 @default.
• W2463147654 countsByYear W24631476542017 @default.
• W2463147654 crossrefType "journal-article" @default.
• W2463147654 hasAuthorship W2463147654A5003656202 @default.
• W2463147654 hasAuthorship W2463147654A5085203627 @default.
• W2463147654 hasConcept C104950815 @default.
• W2463147654 hasConcept C126322002 @default.
• W2463147654 hasConcept C134018914 @default.
• W2463147654 hasConcept C134651460 @default.
• W2463147654 hasConcept C153911025 @default.
• W2463147654 hasConcept C181199279 @default.
• W2463147654 hasConcept C185592680 @default.
• W2463147654 hasConcept C190283241 @default.
• W2463147654 hasConcept C2777482532 @default.
• W2463147654 hasConcept C2780070996 @default.
• W2463147654 hasConcept C2780496750 @default.
• W2463147654 hasConcept C31573885 @default.
• W2463147654 hasConcept C43759708 @default.
• W2463147654 hasConcept C502942594 @default.
• W2463147654 hasConcept C55493867 @default.
• W2463147654 hasConcept C71924100 @default.
• W2463147654 hasConcept C86803240 @default.
• W2463147654 hasConcept C98274493 @default.
• W2463147654 hasConceptScore W2463147654C104950815 @default.
• W2463147654 hasConceptScore W2463147654C126322002 @default.
• W2463147654 hasConceptScore W2463147654C134018914 @default.
• W2463147654 hasConceptScore W2463147654C134651460 @default.
• W2463147654 hasConceptScore W2463147654C153911025 @default.
• W2463147654 hasConceptScore W2463147654C181199279 @default.
• W2463147654 hasConceptScore W2463147654C185592680 @default.
• W2463147654 hasConceptScore W2463147654C190283241 @default.
• W2463147654 hasConceptScore W2463147654C2777482532 @default.
• W2463147654 hasConceptScore W2463147654C2780070996 @default.
• W2463147654 hasConceptScore W2463147654C2780496750 @default.
• W2463147654 hasConceptScore W2463147654C31573885 @default.
• W2463147654 hasConceptScore W2463147654C43759708 @default.
• W2463147654 hasConceptScore W2463147654C502942594 @default.
• W2463147654 hasConceptScore W2463147654C55493867 @default.
• W2463147654 hasConceptScore W2463147654C71924100 @default.
• W2463147654 hasConceptScore W2463147654C86803240 @default.
• W2463147654 hasConceptScore W2463147654C98274493 @default.
• W2463147654 hasIssue "4" @default.
• W2463147654 hasLocation W24631476541 @default.
• W2463147654 hasOpenAccess W2463147654 @default.
• W2463147654 hasPrimaryLocation W24631476541 @default.
• W2463147654 hasRelatedWork W1898156904 @default.
• W2463147654 hasRelatedWork W1967118287 @default.
• W2463147654 hasRelatedWork W2182837698 @default.
• W2463147654 hasRelatedWork W2352517883 @default.
• W2463147654 hasRelatedWork W2376811089 @default.
• W2463147654 hasRelatedWork W2382858276 @default.
• W2463147654 hasRelatedWork W2415662751 @default.
• W2463147654 hasRelatedWork W2443962601 @default.
• W2463147654 hasRelatedWork W2463147654 @default.
• W2463147654 hasRelatedWork W3144925622 @default.
• W2463147654 hasVolume "7" @default.
• W2463147654 isParatext "false" @default.
• W2463147654 isRetracted "false" @default.
• W2463147654 magId "2463147654" @default.
• W2463147654 workType "article" @default.